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Control of developmentally primed erythroid
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How transcription factors (TFs) cooperate within large protein complexes to allow rapid
modulation of gene expression during development is still largely unknown. Here we show
that the key haematopoietic LIM-domain-binding protein-1 (LDB1) TF complex contains
several activator and repressor components that together maintain an erythroid-speciﬁc
gene expression programme primed for rapid activation until differentiation is induced. A
combination of proteomics, functional genomics and in vivo studies presented here identiﬁes
known and novel co-repressors, most notably the ETO2 and IRF2BP2 proteins, involved in
maintaining this primed state. The ETO2–IRF2BP2 axis, interacting with the NCOR1/SMRT
co-repressor complex, suppresses the expression of the vast majority of archetypical
erythroid genes and pathways until its decommissioning at the onset of terminal erythroid
differentiation. Our experiments demonstrate that multimeric regulatory complexes feature
a dynamic interplay between activating and repressing components that determines
lineage-speciﬁc gene expression and cellular differentiation.
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H
aematopoietic development relies on the stepwise
activation and repression of lineage-speciﬁc gene expres-
sion programmes. This process is regulated by sets of
conserved transcription factors (TFs) acting in a combinatorial
and/or antagonistic pattern to establish cellular identity through
tight control of gene regulatory networks1. Exactly how TFs and
the cofactors they recruit cooperate within large protein
complexes to rapidly modulate gene expression during
differentiation is still not completely understood. We set
out to address this issue using a well-characterized erythroid
differentiation system driven by a multimeric TF complex
nucleated by the haematopoietic master regulators LIM-
domain-binding protein 1 (LDB1), GATA-binding protein 1
(GATA1), T-cell acute lymphocytic leukaemia protein 1 (TAL1),
LIM domain-only 2 and eight-twenty-one 2 (ETO2)—hereafter
referred to as the LDB1 complex. The LDB1 complex plays a
pivotal role in promoting differentiation of the erythroid and
megakaryocytic lineages2. It was previously shown to bind the
regulatory regions of developmentally regulated erythroid genes,
which are rapidly induced by the LDB1 complex upon terminal
erythroid differentiation3–7. Despite being already bound by the
LDB1 complex in immature progenitors, premature full
activation of these erythroid genes is prevented by the
LDB1-complex member ETO2 (also referred to as the myeloid-
transforming gene on chromosome 16 or MTG16), a
transcriptional co-repressor3–5,7,8. ETO2 belongs to a family of
transcriptional repressors known as the ETO family, which
further consists of the founder member ETO (or MTG8) and the
myeloid translocation gene, related-1 (MTGR1) proteins. ETO2
plays key roles in the maintenance of haematopoietic stem
cells9, the development of the lymphoid system10 and regulating
effective (stress) erythropoiesis11. The importance of a functional
ETO2 protein in maintaining haematopoietic homeostasis is
further underlined by its causal involvement in acute
leukaemia12–14. Whereas ETO2 is well known for its repressor
function in several cell types3,15,16, the molecular mechanisms of
erythroid gene suppression in the context of the LDB1 complex
remain largely unknown. Unravelling these mechanisms is
important to provide novel insight into how TFs and cofactors
within a multimeric complex impose a ‘primed’ status (that is, a
stage-speciﬁc transcriptional repression of late erythroid genes in
immature progenitors) onto their target genes, which rapidly
switches to full activation at the onset of differentiation.
In this study, to begin addressing these questions, we
performed a proteomics screen for novel ETO2-binding partners.
This screen identiﬁes the interferon regulatory factor 2-binding
protein 2 (IRF2BP2), growth factor-independent 1B (GFI1B) and
lysine-speciﬁc demethylase 1 (LSD1) transcriptional repressors as
ETO2-interacting proteins. We show here that IRF2BP2 is a novel
component of the LDB1 complex able to strongly enhance ETO2-
mediated transcriptional repression. Chromatin immunoprecipi-
tation-sequencing (ChIP-Seq) analysis and loss-of-function
studies reveal that ETO2 and IRF2BP2 chromatin occupancy
signiﬁcantly overlap at a genome-wide scale, and that both factors
regulate a common set of key erythroid target genes and
regulatory pathways. Subsequent analysis of IRF2BP2 protein
partners shows that IRF2BP2 is able to recruit the well-known
NCOR1 co-repressor, which is able to bind ETO2/IRF2BP2
erythroid target genes to potentially mediate their repression. We
ﬁnally conﬁrm the in vivo relevance of the newly identiﬁed
IRF2BP2 co-repressor by using an IRF2BP2-deﬁcient mouse
model. Animals homozygous for the genetrap Irf2bp2 allele
display an ineffective fetal liver (FL) erythropoiesis during
gestation and die around birth. Thus, our data reveal a complex
collaborative action of multiple co-repressor proteins within the
LDB1 complex at the erythroid progenitor stage. As a result, late
erythroid-speciﬁc genes are maintained in a primed state before
their rapid activation upon terminal differentiation.
Results
An epigenetic deﬁnition of primed LDB1 target genes. ‘Primed’
developmentally regulated genes have been previously deﬁned as
being already expressed at low levels before full activation at the
onset of differentiation17. Moreover, TFs responsible for the full
activation of primed genes upon terminal differentiation have
been observed to already bind primed genes at the progenitor
stage18. The late erythroid genes activated by the LDB1 complex
can thus be considered ‘primed’ in undifferentiated erythroid
progenitors, where they are bound by the LDB1 complex but
expressed at low levels5. To more accurately deﬁne their
transcriptional and epigenetic status, we analysed the
expression, TF binding, RNA polymerase II (RNAPII) and
H3K4Me2 levels of primed archetypical erythroid genes in mouse
erythroleukaemia (MEL) erythroid progenitors before and after
the induction of terminal erythroid differentiation. RNA
sequencing (RNA-Seq) analysis shows that primed erythroid
genes are indeed expressed at low—but signiﬁcant—levels in
progenitors and are strongly (±5 fold on average) induced upon
differentiation (Supplementary Fig. 1a). The vast majority (88%)
is already bound by an ETO2-containing LDB1 complex in
progenitors (see ref. 5). Analysis of genome-wide RNAPII
ChIP-Seq data indicates that 495% of the primed genes show
no overt signs of paused RNAPII accumulating at the promoter
before induction, ruling out RNAPII pause-release19 as a general
mechanism of primed gene activation (Supplementary Fig. 1b). In
accordance with low-level expression and strong TF binding, the
active H3K4Me2 chromatin mark is already deposited at the
regulatory elements of primed erythroid genes in progenitors
(Supplementary Fig. 1c). Previously published ChIP-Seq data
obtained from primary erythroid progenitors further conﬁrms
this ﬁnding20 (illustrated in Supplementary Fig. 6e).
We conclude that primed archetypical erythroid genes in
progenitor cells are uniformly deﬁned by: (1) low expression
levels that are strongly induced upon differentiation;
(2) occupancy of the TFs responsible for their later induction;
(3) an active chromatin environment at the regulatory elements
controlling their expression and (4) not having substantial
amounts of paused RNAPII at their promoters. Thus,
primed erythroid genes are subjected to active transcriptional
repression involving ETO2 that prevents their premature
activation5.
Identiﬁcation of ETO2 protein partners in erythroid cells. We
next employed a proteomics approach to characterize the
molecular determinants of ETO2’s repressive activity. An
epitope-tagged form of ETO2 (ETO2-V5-Bio) was stably
expressed in MEL cells5 and used in single-step protein complex
capture experiments21. The afﬁnity tag contains a Bio peptide
sequence that is efﬁciently biotinylated by the bacterial BirA
enzyme, resulting in the biotinylation of ETO2-V5-Bio (Fig. 1a—
full-size images of all western blots shown can be found in
Supplementary Figs 10 and 11). The C-terminal tag fused to
ETO2 does not interfere with its functions, since ETO2-V5-Bio
shows (i) proper intracellular localization (Supplementary
Fig. 2a), (ii) the ability to interact with its known binding
partner LDB1 (ref. 7) (Fig. 1b) and (iii) binding to known
genomic target sites5 (Supplementary Fig. 2c). Thus, tag addition
does not affect ETO2 in its ability to form complexes. A
streptavidin pull-down was carried out and co-puriﬁed proteins
were identiﬁed by mass spectrometry (liquid chromatography–
tandem mass spectrometry (LC–MS)/MS) (Fig. 1c). In addition to
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known components of the LDB1 complex (for example, TAL1,
the E proteins E2A and HEB, single-stranded DNA-binding
protein (SSBP) 2/3/4)7, we also detect additional interactions with
the LSD1/Co-REST repressor complex, the haematopoietic
TF GFI1B and the transcriptional repressor IRF2BP2. MS
analysis of endogenously precipitated ETO2 protein complexes
(immunoprecipitation (IP)–MS) and individual co-IP
experiments in MEL cells conﬁrm the endogenous interaction
of ETO2 with these factors (Fig. 1d; Supplementary Fig. 2).
Whereas the ability of ETO2 to interact with GFI1B was reported
previously3, and the LSD1 protein was found to be associated
with the LDB1 complex (including ETO2) in erythroid cells22, the
involvement of IRF2BP2 in these complexes has not been
reported yet. We therefore set out to investigate this interaction
in more detail.
ETO2 interacts with IRF2BP2 via a unique N-terminal domain.
IRF2BP2 is a highly conserved zinc-ﬁnger/RING-ﬁnger protein
belonging to a family of three evolutionary conserved factors
(IRF2BP1, IRF2BP2 and IRF2BPL) sharing high sequence
homology. IRF2BP1 and IRF2BP2 were originally identiﬁed as
interacting partners of IRF2, mediating its ability to repress
in vitro reporter expression23. Recently, several other studies
reported a repressive role for IRF2BP2 in complex with nuclear
factor of activated T-cells 1 (NFAT1)24, p53 (ref. 25) or enhanced
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Figure 1 | Identiﬁcation of ETO2-binding partners in erythroid progenitor cells. (a) Schematic of the ETO2 protein, its 4 Nervy homology regions
(NHR1-4) and the C-terminal V5-Bio tag (top). Fusion protein expression and proper tag function in MEL cells were validated by WB analysis. MEL cells
expressing only the BirA enzyme were used as a control. (b) Efﬁcient streptavidin IP of ETO2-V5-Bio in MEL cells. Interaction of ETO2-V5-Bio with LDB1
(a known binding partner) was used for validation. (c) ETO2-V5-Bio-interacting proteins identiﬁed by LC–MS/MS in MEL cells. Only proteins pulled down
in two independent experiments and with low background scores are shown. (d) Co-IP validations of selected ETO2-V5-Bio-interacting proteins in MEL
cells using an endogenous ETO2 antibody. Species-matched IgG was used to control for aspeciﬁc binding. Full-size images of all western blots shown can
be found in Supplementary Fig. 10. Strept-HRP, streptavidin-HRP; Sup, supernatant; endog., endogenous; WB, western blot; IP, immunoprecipitation.
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at puberty 1 (EAP1)26, although an activating role for IRF2BP2 in
regulating VEGFA expression has been described as well27. To
map the domains mediating the interaction between ETO2 and
IRF2BP2, a series of deletion mutants was generated and used in
co-IP experiments. ETO2 contains four highly conserved domains
(nervy homology regions 1–4) shared with the other members of
the ETO family (ETO and MTGR1)28, but also two unique
sequences at its N terminus not shared with ETO/MTGR1, which
we termed Unique Sequence 1 and 2 (US1/2) (Fig. 2a). As shown
in Fig. 2b, ETO2 interacts with IRF2BP2 via its US2 domain,
suggesting that ETO2 is the only protein from the ETO family able
to bind IRF2BP2. Using a similar strategy, we ﬁnd that the
IRF2BP2 RING-ﬁnger domain mediates the interaction with
ETO2 (Fig. 2c). RING-ﬁnger domains are characteristic of E3
ubiquitin ligases catalysing the ubiquitination of target proteins,
which often leads to protein degradation29. Since ETO2 interacts
with the RING-ﬁnger domain of IRF2BP2, we tested whether
ETO2 stability could be affected by this interaction. Increasing
amounts of IRF2BP2 were co-expressed together with ETO2 in
HEK 293T cells, and ETO2 protein levels were monitored by
western blot analysis. As shown in Supplementary Fig. 3, even
when expressed in large excess, IRF2BP2 does not signiﬁcantly
affect ETO2 protein levels under these conditions.
IRF2BP2 enhances ETO2-mediated transcriptional repression.
The functional role of the ETO2–IRF2BP2 interaction was ﬁrst
investigated in vitro using luciferase reporter assays. ETO2 was
fused to a Gal4 DNA-binding domain and co-expressed in HEK
293T cells together with a luciferase reporter plasmid containing
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Gal4-responsive elements. As previously reported, ETO2 induces
a 20–30-fold repression of luciferase activity (Fig. 2d)30.
Co-expression of IRF2BP2 further increases ETO2-mediated
transcriptional repression in a dose-dependent manner. This
effect is not seen when using a RING-ﬁnger deletion mutant of
IRF2BP2 (IRF2BP2deltaRING) unable to interact with ETO2.
Importantly, the ETO2-interacting partner LSD1 (Fig. 1c,d), a
known transcriptional repressor, does not signiﬁcantly enhance
ETO2-mediated repression (Fig. 2d) despite its ability to interact
with ETO2 in HEK cells (Supplementary Fig. 3b).
Genome-wide analysis of ETO2 and IRF2BP2 chromatin binding.
We next performed ChIP-Seq experiments to determine whether
IRF2BP2 is enriched at critical regulatory sites occupied by ETO2. In
erythroid progenitors, IRF2BP2-binding sites occur at numerous cis-
regulatory regions of late erythroid genes controlled by ETO2 and
LDB1. For example, IRF2BP2 and ETO2 show co-occupancy on the
Gypa, Slc22a4, Epb4.2, Alas2 and Slc4a1 genes, as well as the a- and
b-globin clusters (see Fig. 3a for examples). These genes are critical
markers of mature erythroid cells and reside in a primed state in
erythroid progenitors such as MEL cells5,6 (Supplementary Fig. 1).
This suggests that IRF2BP2 might cooperate with ETO2 to maintain
these erythroid genes in a primed state, suppressing the actions
of the other LDB1-complex members required for their
rapid activation upon terminal differentiation2,6. A genome-wide
comparison of ETO2- and IRF2BP2-binding patterns revealed that
61% of ETO2-binding sites are also occupied by IRF2BP2 (Fig. 3b).
However, many genomic locations are bound by IRF2BP2 in the
absence of ETO2 and vice versa (Fig. 3c), indicating that both
proteins are also involved in different regulatory complexes.
Analysing peak distribution relative to transcription start sites
(TSSs) (using Genomic Regions Enrichment of Annotations Tool
(GREAT)31, see Methods) reveals that both common and ETO2-
speciﬁc binding occurs predominantly (480%) distal (45 kb) from
a TSS (Supplementary Fig. 4), in agreement with the binding
distribution of the LDB1 complex5. However, IRF2BP2-only peaks
show signiﬁcantly more (42%) proximal promoter (o5kb of the
TSS) binding. Interestingly, the LSD1 and GFI1B repressors are also
found enriched at ETO2/IRF2BP2-binding sites, overlapping with
the positioning of the LDB1 complex (Supplementary Fig. 5).
We tried to substantiate these observations on ETO2 and
IRF2BP2 chromatin occupancy by performing a Gene Ontology
term analysis on putative target genes assigned to the different
binding site subsets using GREAT. This conﬁrms a strong
enrichment for erythroid functions among the common target
genes (Fig. 3b). ETO2-speciﬁc target genes show some enrich-
ment for common blood-cell-related functions, as well as for
several housekeeping processes. Intriguingly, IRF2BP2-speciﬁc
target genes show strong associations with biological processes
and functions involved in survival, apoptosis and cancer (Fig. 3b).
A de novo DNA motif search performed on ETO2- and
IRF2BP2-occupied genomic binding sites reveals an enrichment
of several different TF-binding motifs. ETS (E-twenty-six, for
example, the Friend leukaemia integration 1 (FLI1)/ETS-related
gene (ERG) TFs) and G/C-rich (early growth response (EGR)
family) TF motifs were detected in all three categories, while
Runt-related TF (RUNX) and TCF motifs show enrichment at
sites occupied only by IRF2BP2 (Fig. 3d). Strikingly, nearly all
ETO2-only and ETO2–IRF2BP2 shared sites contain the typical
LDB1-complex signature represented by a composite E-box/
GATA motif (CTGN(6–8)WGATAR)5,32, while this motif is
completely absent from the IRF2BP2-only-binding sites (Fig. 3d).
This shows that in MEL cells, the IRF2BP2-only-binding sites are
LDB1-complex independent. However, IRF2BP2-only sites did
show some enrichment for GATA motifs, indicating that a small
subset of these sites could be GATA1-targeted. Interestingly,
IRF2BP2-only sites are speciﬁcally enriched for several other TF
motifs, including CCCTC-binding factor (CTCF), Speciﬁcity
protein/Kru¨ppel-like factor (SP/KLF) and leucine zipper (that is,
activating protein-1 family) TF motifs.
Irf2bp2 expression during erythroid differentiation. It is well
established that ETO2 expression levels diminish as erythroid
progenitors undergo terminal differentiation3,4,7. Furthermore, in
a G1E-ER model system of erythroid differentiation, expression
of Cbfa2t3 (encoding ETO2) was repressed upon GATA1-driven
erythroid maturation33,34. These and other observations34 suggest
that Cbfa2t3 expression is regulated by the ETO2-containing
LDB1 complex, which involves an ETO2 negative autoregulatory
loop. To gain more insight into the regulation of Irf2bp2 during
erythropoiesis, we examined its expression levels during mouse
FL erythropoiesis. RNA-Seq analysis of ﬂuorescence-activated cell
sorting (FACS)-puriﬁed populations of developing erythroid cells
(the same populations as shown in Fig. 7i,j, see the Methods
section for more details) indicates that Irf2bp2 expression is
reduced upon differentiation (Fig. 4a). These observations are
further validated by quantitative PCR (qPCR) experiments
(Supplementary Figs 8 and 9). A similar trend was observed by
others using various in vivo and in vitro model systems for
erythroid development35,36 (Fig. 4b,c). As was reported for
Cbfa2t3, Irf2bp2 expression is lost upon GATA1-driven erythroid
maturation in a G1E-ER model system (Fig. 4c). In
addition, using genome-wide data sets previously generated by
our laboratory5 and the Encyclopedia Of DNA Elements
(ENCODE) consortium36, we identify two putative enhancer
elements within the Irf2bp2 locus bound by the ETO2/IRF2BP2-
containing LDB1 complex (Fig. 4d–f). When G1E-ER cells are
differentiated by translocation of GATA1 into the nucleus, the
TAL1 activator2,5,32,37 is displaced from these putative regulatory
elements (Fig. 4f), along with a loss of Irf2bp2 expression (Fig. 4c)
and RNAPII occupancy of the locus (Fig. 4f). Collectively, these
data indicate that during erythroid differentiation Irf2bp2
expression is repressed in a GATA1-dependent manner. We
speculate that, similar to events observed at the Cbfa2t3 locus34,
Irf2bp2 regulation involves negative auto-regulation by ETO2/
IRF2BP2.
Figure 3 | ETO2–IRF2BP2 genomic co-occupancy is associated with genes involved in key erythroid processes. (a) Selected examples of overlapping
ChIP-Seq proﬁles for LDB1, IRF2BP2 and ETO2 in MEL cells on key erythroid gene loci. (b) Venn diagram showing the genome-wide overlap between
ETO2- and IRF2BP2-binding sites in MEL cells. GREATanalysis31 (see Methods for more details) was performed for each group of binding sites (ETO2 only,
co-occupied and IRF2BP2 only) to identify their putative target genes and possible signiﬁcantly associated Gene Ontology (GO) terms. The top 15 GO
terms are shown for each group of binding sites, and individual GO terms were categorized into four classes (erythroid-related, non-erythroid blood-related,
proliferation/survival-related and housekeeping/unrelated). (c) Heatmap visualization of ETO2 and IRF2BP2 ChIP-Seq data, depicting all signiﬁcant binding
events centred on the peak region within a 1-kb window around the peak (binding sites were ranked on intensity). (d) A motif analysis (see Methods for
more details) on the three groups of binding sites (ETO2 only, co-occupied and IRF2BP2 only) was performed to identify possible over-represented
transcription factor-binding motifs within the peak sequences. Red numbers denote (number of motifs)/(total number of binding sites).
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An IRF2BP2–ETO2 axis imposes transcriptional repression.
We next tried to address the functional roles played by ETO2 and
IRF2BP2 in erythroid cells. Short hairpin RNA (shRNA)-
mediated knockdowns (KDs) of Cbfa2t3 and Irf2bp2 were per-
formed in MEL cells, after which the expression of several ETO2-
LDB1 target genes was measured. As shown in Fig. 5, depleting
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ETO2 (Fig. 5a) or IRF2BP2 (Fig. 5b) results in increased Alas2,
Epb4.2, Gypa and Slc22a4 expression levels, establishing the
repressive roles of ETO2 and IRF2BP2 in regulating primed
archetypical erythroid genes. This result also corroborates that
ETO2 and IRF2BP2 form a functional erythroid co-repressor
complex. In marked contrast, when performing the same
experiments for LSD1 (encoded by the Kdm1a gene, Fig. 5c),
which co-occupies the same genes (Supplementary Fig. 5a), either
very minor changes (Alas2, Gypa, Slc22a4) or decreased expres-
sion (Epb4.2) is observed. This result, together with the data
derived from the reporter assays (Fig. 2d) suggest that LSD1 does
not mediate transcriptional repression by ETO2 and might even
play an opposite role. To more comprehensively identify genes
controlled by ETO2 and IRF2BP2, transcriptome analyses were
carried out by RNA-Seq after ETO2 and IRF2BP2 depletion in
MEL cells. Differentially expressed genes were also compared
with the ones obtained after LSD1 depletion. Strikingly, we
observe a high degree of correlation when comparing genes
signiﬁcantly misregulated after ETO2 or IRF2BP2 KD (Fig. 5d,e),
showing that genes controlled by ETO2 are also regulated by
IRF2BP2, both in a positive and negative manner. Conversely,
comparison of genes misregulated in both the Cbfa2t3 (ETO2)
and Kdm1a (LSD1) KD shows an inverse trend, as genes
repressed by ETO2 are activated by LSD1 and vice versa
(Fig. 5d,f). In addition, the KD of another ETO2-interacting
repressor Gﬁ1b (encoding GFI1B), which is known to interact
with both ETO2 and LSD1, results in a very similar proﬁle
of differentially expressed genes when compared with the
Cbfa2t3 and Irf2bp2 KD results (Fig. 5d). This suggests that
ETO2, IRF2BP2 and GFI1B negatively regulate a set of
common genes and form a repressive complex in erythroid
progenitor cells. Finally, we compared misregulated genes from
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the ETO2-, IRF2BP2- and LSD1-depletion experiments to the
gene expression changes obtained after MEL cell differentiation
(Fig. 5g). The emerging correlations conﬁrm the results presented
in Fig. 5a–c: genes derepressed upon ETO2/IRF2BP2 depletion
are upregulated during erythroid differentiation (including many
of the primed terminal erythroid differentiation genes, Fig. 5g),
while the opposite trend emerges for LSD1.
We next conducted rescue experiments in which wild-type
Cbfa2t3/Irf2bp2 or loss-of-interaction mutant complementary
DNAs (cDNAs) were transfected into ETO2/IRF2BP2-depleted
MEL cells (Fig. 5h). While the introduction of wild-type cDNA
restores erythroid gene repression (Fig. 5h, orange bars), mutant
cDNAs encoding ETO2/IRF2BP2 proteins no longer able to
interact with each other (see Fig. 2) cannot or only partially
induce transcriptional repression (Fig. 5h, grey bars). These
experiments conﬁrm that in erythroid progenitors ETO2 and
IRF2BP2 function as transcriptional repressors in a highly
cooperative manner. Moreover, IRF2BP2 ChIP experiments in
an ETO2-deﬁcient MEL cell line (generated using CRISPR/Cas9
technology38, see the Methods section) reveal a loss of chromatin
binding in the absence of ETO2 (Fig. 5i). The reciprocal
experiment—ETO2 ChIPs in an IRF2BP2 / MEL cell line—
shows that ETO2 binding to the genome does not strictly rely on
IRF2BP2 (Fig. 5i). Of note, the core LDB1 complex remains
bound at the examined regulatory sites in the absence of ETO2 or
IRF2BP2—ruling out the possibility of a global disruption of
LDB1-complex recruitment in these cells (Supplementary
Fig. 5b).
IRF2BP2 and ETO2 repress essential erythroid pathways. To
obtain functional insight into the genes affected in the Cbfa2t3
and Irf2bp2 KD experiments, we applied Ingenuity Pathway
Analysis on the misregulated genes to link the transcriptional
regulatory activities of ETO2 and IRF2BP2 to biological func-
tions. In MEL cells, 2,625 genes are found differentially expressed
upon IRF2BP2 depletion, and 724 upon ETO2 depletion. Com-
bining these data sets, 58% of the ETO2 misregulated genes (420)
are also found affected in the IRF2BP2 data set (Fig. 6a).
Approximately 55% of the commonly misregulated genes are
found upregulated and therefore appear to be repressed by ETO2/
IRF2BP2. These 234 genes are highly enriched for erythroid
functions (Fig. 6b).
In fact, 71% of the genes coding for the major components of
the haem biosynthesis pathway are bound (as determined by
GREAT analysis, see Methods) by ETO2 and IRF2BP2 (Fig. 6c;
left graph). Furthermore, over 77% of the erythrocyte-speciﬁc
membrane structural components and ion transporters are also
targeted by the ETO2/IRF2BP2 complex (Fig. 6c; right graph).
In correspondence with this binding pattern, almost all of the
above mentioned erythroid genes are misregulated upon ETO2
and/or IRF2BP2 depletion (100% of the haem biosynthesis genes
and 78% of the erythrocyte membrane proteins are affected in at
least one KD, see Fig. 6c), with a strong preference for
derepression. In agreement with their co-occupancy by both
proteins, many genes are upregulated after either Cbfa2t3 or
Irf2bp2 KD (71% of haem biosynthesis genes and 36% of
erythrocyte membrane protein genes, see Fig. 6c). In addition,
a- and b-globin gene activation was observed in both KD
experiments (Irf2bp2 KD—Hba-a1/2: 8.2-fold up, Hbb-b1/2:
4.0-fold up; Cbfa2t3 KD—Hba-a1/2: 3.9-fold up, Hbb-b1/2:
1.7-fold up). In general, 30–40% of the genes misregulated upon
either Cbfa2t3 or Irf2bp2 KD are also bound by the corresponding
factor (Fig. 6d), despite the inevitable presence of indirectly
affected genes within our sets of putative targets. Strikingly, 70%
of the genes bound and regulated by both ETO2 and IRF2BP2 in
erythroid progenitors are found to be repressed, and these genes
again exhibit a signiﬁcant enrichment for erythroid functions
(Fig. 6d). Together, these observations strongly indicate that the
ETO2/IRF2BP2 complex controls the expression of key genes
critical for erythroid cell identity and function.
ETO2 and IRF2BP2 also modulate a set of 186 genes that are
downregulated upon factor depletion (Fig. 6b), of which 28%
were also co-occupied. This suggests that ETO2/IRF2BP2-
containing complexes can also function in gene activation.
Over-represented among these are genes known to play a role
in blood cell activation, proliferation and cell death (Fig. 6b). Such
pathways are known to be suppressed upon erythroid differentia-
tion and might (in part) be activated by ETO2/IRF2BP2 in
progenitor cells39. Surprisingly, a large fraction of the over-
represented processes are related to leukocyte and lymphocyte
biology (Fig. 6b).
IRF2BP2 interacts with NCOR co-repressor proteins. Although
our data strongly suggest a repressor function for IRF2BP2 in
erythroid gene regulation, how IRF2BP2 achieves gene repression
is still unclear. We therefore puriﬁed endogenous IRF2BP2-con-
taining protein complexes from MEL cells and identiﬁed the
interacting proteins by IP-MS. As shown in Fig. 7, we retrieve
known interacting proteins such as the other IRF2BP family
members23 and several LDB1-complex members. In addition,
IRF2BP2 also interacts with proteins involved in the cell cycle and
transcriptional regulation (Fig. 7b). Among the latter group are
several protein complexes known to mediate transcriptional
repression. Prominent among these is the nuclear receptor co-
repressor/silencing mediator for retinoid and thyroid receptors
(NCOR/SMRT) co-repressor complex. Key components of this
Figure 5 | Genome-wide analysis of gene expression changes shows that ETO2 and IRF2BP2 repress the late erythroid transcriptome. Lentiviral
delivery of shRNAs against Cbfa2t3 (a), Irf2bp2 (b) and Kdm1a (c) mRNA to deplete MEL cells of the ETO2, LSD1 and IRF2BP2 proteins, respectively. A non-
targeting shRNA (Ctrl) was used as a control. After 72 h, mRNA levels were measured by qPCR (normalized versus Rnh1 levels) or protein levels by western
blot (actin and AURKA were used as loading controls). Expression levels of four archetypical late erythroid genes (Alas2, Epb4.2, Gypa and Slc22a4) were
quantiﬁed by qPCR. (d) Unsupervised clustering of the top 142 misregulated genes after Cbfa2t3 (ETO2) KD and the expression changes of the same set of
genes induced after GFI1B, IRF2BP2 and LSD1 depletion. Gene expression changes are shown as log2 fold change (FC). (e–g) Correlations between gene
expression changes (log2 FC) after ETO2/IRF2BP2/LSD1 KD (72 h post transduction) or MEL cell differentiation (96 h). Red dots represent individual genes
(see Methods for more information on thresholds used). Positions of archetypical late erythroid genes (for example, Alas2, Epb4.2 and Gypa) within the
graphs are indicated. (h) MEL cells transduced with Cbfa2t3-sh3 (top) and Irf2bp2-sh1 (panel) lentiviruses were transfected with empty pcDNA3.1 vector
(Ctrl), wild-type cDNA or with an interaction-deﬁcient mutant Cbfa2t3 or Irf2bp2 cDNA (also see Fig. 2). Gene expression of three late erythroid genes was
measured 48 h after transfection by qPCR (normalized versus Rnh1 levels). (i) ChIP-qPCR experiments for ETO2 and IRF2BP2 in parental wild-type (WT)
MEL cells, ETO2 / and BP2 / MEL cell lines generated using CRISPR/Cas9 technology. Protein binding was examined on the regulatory regions of
Alas2, Slc22a4, Epb4.2 and Gypa. Species-matched IgG was used as a negative control. All bars represent averages of at least two independent experiments;
error bars denote s.d. Full-size images of all western blots shown can be found in Supplementary Fig. 11.
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complex are the NCOR1 and 2 proteins (the latter is also known
as SMRT), and their repressive actions have been well
documented40. Intriguingly, Ncor1 / mice die in utero due
to abnormal erythropoiesis41. To test whether NCOR proteins are
indeed recruited to the regulatory elements of ETO2/IRF2BP2
target genes in erythroid progenitors, we performed NCOR1
ChIP-Seq in MEL cells. This reveals a signiﬁcant overlap between
NCOR1- and ETO2/IRF2BP2-binding sites (1,164 sites, Fig. 7c,d).
In accordance with a possible cooperative relationship between
these proteins, we ﬁnd that these co-occupied sites include464%
of the primed erythroid-speciﬁc genes involved in haem
biosynthesis and red cell membrane function (Fig. 7c,d).
Furthermore, the ETO2–IRF2BP2–NCOR1 triad occupies key
regulatory elements within the a- and b-globin loci
(Supplementary Fig. 5c).
We next sought to perturb NCOR1 activity to assess its
contribution to ETO2/IRF2BP2 target gene repression in
erythroid progenitors. Multiple attempts at depleting NCOR1
levels in MEL cells using RNA interference (RNAi) (via both
lentiviral shRNA delivery and short interfering RNA (siRNA)
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Figure 6 | The ETO2–IRF2BP2 axis directly controls the expression of key haem biosynthesis and erythrocyte membrane proteins. (a) Venn diagram of
differentially expressed genes (log2 FC40.5/0.5, Po0.05) after ETO2 or IRF2BP2 depletion in MEL cells. (b) Venn diagrams of upregulated genes (top,
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transfections) failed to provide consistent effects on erythroid
gene expression between individual shRNAs/siRNAs (n¼ 3–4 for
each, Supplementary Fig. 6). We believe that the numerous Ncor1
isoforms expressed in MEL cells (as assessed by RNA-Seq,
Supplementary Fig. 6) could contribute to the inconsistent effects
seen with the different RNAi constructs, as alternative splicing
has been reported to generate many functionally distinct NCOR1
isoforms40,42. In an attempt to inhibit NCOR1 protein function in
a different manner, we decided to target the histone deacetylase 3
(HDAC3) that mediates the repressive actions of NCOR1
(reviewed in ref. 40). Apicidin is a small-molecule HDAC
inhibitor reported to have speciﬁcity for HDAC3 (ref. 43), and we
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therefore treated MEL cells with 100 nM apicidin and measured
erythroid gene expression after 24 h. Robust derepression of
ETO2/IRF2BP2 target gene expression is observed after treatment
(Supplementary Fig. 6), strengthening the hypothesis that
NCOR1, through HDAC3, represses ETO2/IRF2BP2 target gene
expression in erythroid progenitors. In addition, we observe a
positive change in the ratio of LDB1/NCOR1 binding to the
regulatory sequences of primed erythroid genes in differentiating
MEL cells (Supplementary Fig. 6). This indicates that terminal
erythroid differentiation is associated with a decreasing relative
abundance of repressors such as NCOR1 as compared with
activators (for example, LDB1) bound at late erythroid genes, as
previously observed for ETO2 (ref. 5). Finally, an examination of
published ChIP-Seq data20 shows that histone acetylation levels
on known NCOR1/HDAC3 target residues44,45 at ETO2/
IRF2BP2/NCOR1-bound erythroid genes frequently increases
during erythroid differentiation (Supplementary Fig. 6),
concomitant with diminished ETO2 (refs 3,4) and IRF2BP2
(Fig. 4) expression. Together, these data indeed suggest that
IRF2BP2-mediated gene repression involves the NCOR1 co-
repressor complex.
IRF2BP2-deﬁcient mice show abnormal FL erythropoiesis.
Next, we interrogated IRF2BP2 function in vivo. For this purpose,
we used an IRF2BP2-deﬁcient mouse model generated by a
genetrap strategy (Fig. 7e). The genetrap vector (containing a
strong splice acceptor) was retrovirally inserted in the Irf2bp2
intron and results in a complete disruption of full-length mes-
senger RNA (mRNA) production (Fig. 7e–g). Animals homo-
zygous for the Irf2bp2 genetrap allele (hereafter referred to as
Irf2bp2trp/trp mice) are rarely obtained and did not survive past 4
weeks of age, displaying severe growth retardation. In fact,
although Irf2bp2trp/trp embryos appear to develop normally up to
E18.5 and are obtained at the expected Mendelian ratio, live
births are very rare (o5% of the expected number). This indi-
cates that Irf2bp2trp/trp mice die either late during gestation or
immediately after birth. Given that Irf2bp2 expression is parti-
cularly high in the developing mouse lungs, skeletal muscle and
heart at E17.5 (ref. 27), defects in these tissues might underlie the
observed lethality. To determine whether deﬁnitive erythropoiesis
is affected in these mice, we collected E13.5 FL tissue from litters
obtained after crossing Irf2bp2trp/wt mice. At this stage of murine
embryonic development, the FL is the main site of deﬁnitive
haematopoiesis and consists mainly of developing erythrocytes1.
Irf2bp2trp/trp FLs show reduced total cellularity (Fig. 7h). When
stained with antibodies against the developmental CD71 and
Ter119 surface markers, erythropoiesis in Irf2bp2trp/trp FLs shows
several defects (Fig. 7i). We observe a marked reduction in the
double-negative immature progenitor compartment, while cells
belonging to the more mature erythroblast stages (the CD71þ
Ter119 and double-positive stages) are more abundant in
Irf2bp2trp/trp FLs. Furthermore, the relative number of mature
Ter119þCD71 erythrocytes is signiﬁcantly reduced in the
absence of IRF2BP2. These data indicate that IRF2BP2 is
important for effective FL erythropoiesis, as the output of
mature erythrocytes is impaired in the absence of a functional
Irf2bp2 allele.
We further characterized terminal differentiation in
Irf2bp2trp/trp FLs by separating the Ter119þ population based
on its forward scatter (FSC) proﬁle46 (Fig. 7j). As erythroid
differentiation is paralleled by a reduction in cell size, this analysis
visualizes a terminal differentiation gradient ranging from large
and nucleated cells (high FSC) to small, enucleated cells (low
FSC). Early enucleating cells (medium FSC) are more abundantly
present in IRF2BP2-deﬁcient FLs, while the percentage of small
and enucleated erythrocytes is reduced (Fig. 7j).
FL erythropoiesis at earlier developmental time points (E11.5
and E12.5) also shows altered proportions of the different
developing erythroid populations in Irf2bp2trp/trp embryos—in
particular, within the mature Ter119þ compartment
(Supplementary Fig. 7). Defects observed at E12.5 are similar in
nature to the E13.5 phenotype, while at E11.5 erythropoiesis
seems less severely affected: Irf2bp2trp/trp FLs exhibit a modest
decrease in pro-erythroblast abundance and an increased
presence of small terminally differentiated red cells. Moreover,
gene expression analysis of selected ETO2/IRF2BP2 target genes
(as identiﬁed in MEL cells) in sorted FL erythroid populations
reveals an upregulation of these late erythroid markers in
Irf2bp2trp/trp red cell precursors, as well as a downregulation of
Myb expression—a marker for early erythroid progenitors
(Supplementary Figs 8 and 9). Derepression of primed late
erythroid genes is most striking at E11.5 and diminished at E13.5.
Intriguingly, we observe a signiﬁcant upregulation of the related
Irf2bpl gene in Irf2bp2trp/trp early erythroid precursors
(Supplementary Figs 8 and 9). This phenomenon was most
prominent at E13.5 and could indicate the existence of a
compensatory mechanism involving IRF2BPL.
Combined, these observations point at disturbed erythroid
differentiation kinetics and transcriptional regulation in the
absence of IRF2BP2, conﬁrming the notion that IRF2BP2 is
important for effective erythropoiesis in vivo.
Discussion
Developmental processes are coordinated by spatio-temporal
changes in gene expression laid down by the combinatorial
actions of TFs and the cofactors they recruit. Exactly how TFs in
Figure 7 | Characterization of IRF2BP2 protein partners and fetal liver erythropoiesis in IRF2BP2-deﬁcient mice. (a) Coomassie staining of IRF2BP2 and
control IgG-immunoprecipitated proteins separated by SDS–polyacrylamide gel electrophoresis. (b) IRF2BP2-interacting proteins identiﬁed by LC–MS/MS
in MEL cells. Proteins pulled down in two independent experiments and with low background scores are shown, except for HDAC3 (*—only detected in one
pull down). (c) Examples of NCOR1 recruitment to IRF2BP2-binding sites. (d) Venn diagram showing the genome-wide overlap between ETO2-, IRF2BP2-
and NCOR1-binding sites in MEL cells. Note the signiﬁcant co-localization of all three factors on the chromatin (1,164 sites), which included the a- and
b-globin loci and 464% of haem biosynthesis and erythrocyte membrane protein genes shown in Fig. 6c. (e) A genetrap vector (containing a strong
splice-acceptor (SA) and a polyadenylation sequence (pA)) was retrovirally inserted in the Irf2bp2 intron to disrupt full-length mRNA production (genetrap
allele is referred to as ‘Irf2bp2trp’). (f) Typical genotyping results obtained from a standard 3-primer PCR strategy. (g) Irf2bp2 mRNA levels in whole fetal
livers (FL) from E13.5 mouse embryos with the indicated genotypes (n¼4–6 embryos per genotype, normalized to Rnh1 levels). (h) Total FL cellularity in
E13.5 embryos with the indicated genotypes (n¼ 5–21 embryos per genotype). (i,j) Flow cytometry analysis (CD71-Ter119 double-staining) of FLs from
E13.5 embryos with the indicated genotypes (n¼ 9–11 embryos per genotype). Representative ﬂow cytometry plots are shown on top; average values are
plotted as bar graphs underneath. (i) A quadrant analysis of CD71-Ter119 staining on all live (Hoechst negative) single cells to visualize erythroid
differentiation. (j) Ter119þ FL cells separated into three populations based on the FSC proﬁle46. Differences between wild-type and Irf2bp2trp/trp embryos
were tested for statistical signiﬁcance (Mann–Whitney U-test; *Po0.05, **Po0.01, ***Po0.001). Error bars denote s.d. NS, not signiﬁcant.
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large multimeric complexes cooperate to create a regulatory
environment that allows for rapid modulation of gene expression
programmes is under intense investigation. Here we address the
observation of a master haematopoietic TF complex, containing
key factors required for the activation of a tissue-speciﬁc gene
expression programme, that binds its target genes but maintains
them in a developmental stage-speciﬁc primed state. Previous
studies have shown that the activating LDB1 TF complex is
already recruited to genes of the late erythroid-speciﬁc tran-
scriptome in erythroid progenitors, before their full activation3–7.
We have further conﬁrmed and characterized the transcriptional
and epigenetic status of these primed erythroid genes, revealing
that they reside in active chromatin and are not controlled
through an RNAPII pause–release mechanism19. One particular
complex member, the ETO2 co-repressor, was found to mediate
priming by repressing LDB1-complex target gene expression3–5,7.
ETO2-mediated repression remains poorly understood, although
the GFI1B TF, HDACs and the SIN3 transcription regulator
family member A (Sin3A) repressor protein have been implicated
(either directly or via their interaction with TAL1)3,30,47. We set
out to further investigate the molecular mechanisms used by
ETO2 to suppress terminal erythroid gene expression in
progenitor cells.
A proteomics approach was ﬁrst used to catalogue ETO2-
interacting proteins in MEL erythroid progenitors (Fig. 1),
identifying several repressor candidates known to bind ETO2 or
other LDB1-complex members (for example, GFI1B3 and LSD1
(ref. 22)). Interestingly, we also detect the IRF2BP2 co-repressor
in our interaction screen. Follow-up experiments ﬁrmly establish
a cooperative role for ETO2 and IRF2BP2 in maintaining the late
erythroid transcriptional programme in a primed state in
undifferentiated progenitors: (1) IRF2BP2 strongly enhances
ETO2-mediated repression in vitro, which is fully dependent on
the ETO2–IRF2BP2 interaction (Fig. 2); (2) ETO2 and IRF2BP2
chromatin occupancy shows extensive genome-wide co-
localization at genes involved in red blood cell development
and function (Fig. 3); (3) similar to Cbfa2t3 (ETO2), Irf2bp2
expression is reduced upon erythroid differentiation, concomitant
with the upregulation of its erythroid target genes (Fig. 4); (4)
depletion of ETO2 or IRF2BP2 leads to overlapping effects on
gene expression, in particular the strong derepression of the late
erythroid-speciﬁc transcriptome (Fig. 5); (5) ETO2/IRF2BP2
mutant proteins unable to interact with each other show impaired
induction of erythroid gene repression (Fig. 5); (6) ETO2 and
IRF2BP2 bind the regulatory regions of 470% of the critical
haem biosynthesis and erythrocyte membrane genes, the majority
of which are repressed by both factors (Fig. 6).
Our biochemical analyses of IRF2BP2 protein complexes in
MEL cells reveal the presence of NCOR/SMRT co-repressor
complex members (Fig. 7b). In accordance, a key component of
this complex, NCOR1, shows extensive genomic co-occupancy
with IRF2BP2 and the ETO2/LDB1 complex in erythroid
progenitors (Fig. 7d). Among these co-occupied sites, we ﬁnd
the vast majority of ETO2/IRF2BP2-repressed erythroid genes.
Inhibition of NCOR1 complex activity by the apicidin inhibitor
results in the upregulation of genes repressed by ETO2 and
IRF2BP2 (Supplementary Fig. 6). On the basis of these data, we
propose that IRF2BP2 confers repression upon ETO2/LDB1-
complex target genes in part via its interaction with the NCOR/
SMRT co-repressor complex. In accordance with our hypothesis,
NCOR1-deﬁcient mice showed abnormal FL erythropoiesis and
developed severe anaemia during mid-gestation41.
We have also investigated the role of other ETO2-interacting
putative repressor proteins. Although we could not detect Sin3A
in our ETO2 IPs from erythroid cell lines, we did ﬁnd the GFI1B
TF and the LSD1 lysine demethylase, both of which have been
implicated in the repression of LDB1-complex target genes3,22,48.
Both proteins colocalize with the ETO2-containing LDB1
complex on the erythroid progenitor genome (Supplementary
Fig. 5). In discordance with the ﬁndings of Hu et al.22, we ﬁnd no
evidence for LSD1-mediated repression of the erythroid-speciﬁc
Epb4.2 gene (Fig. 5). In fact, we observe the opposite effect of
LSD1 depletion on the late red cell transcriptome when compared
with the Cbfa2t3/Irf2bp2 KDs (Fig. 5), similar to the loss of
erythroid marker expression and differentiation upon LSD1 KD
reported by Saleque et al.49. We conclude that LSD1, as part of
the LDB1 complex, in general fulﬁlls an activating role in
erythroid differentiation (that is, possibly through controlling
H3K4 methylation status50). In contrast, GFI1B, a DNA-binding
repressor previously found to be required for terminal erythroid
differentiation51, appears to repress LDB1-complex target genes
in a similar manner as ETO2/IRF2BP2 (Fig. 5d). As was reported
for ETO2, interactions between GFI1B and the activating LDB1-
complex member TAL1 were strongly diminished upon terminal
erythroid differentiation3. Cooperation of GFI1B with ETO2 and
IRF2BP2 seems a plausible scenario warranting further
investigation.
Intriguingly, IRF2BP2 binds many genomic regions indepen-
dent of ETO2 and the LDB1 complex (Fig. 3). IRF2BP2-only sites
are generally located closer to TSSs and therefore appear more
frequently involved in short-range or promoter-based gene
regulation as compared with LDB1-complex-associated IRF2BP2
sites (Supplementary Fig. 4). Furthermore, IRF2BP2 depletion
affected the expression of numerous genes in an ETO2-
independent fashion (Fig. 6). These observations suggest that
IRF2BP2 plays additional roles in erythroid progenitors, inde-
pendent of ETO2 and the LDB1 complex. In such cases, targeting
of IRF2BP2 to the DNA could be mediated by ETS, TCF and
EGR/SP family TFs, as binding motifs for these factors are
strongly enriched at sites only bound by IRF2BP2 (Fig. 3c,d).
Surprisingly, we did not detect a signiﬁcant enrichment of IRF-
binding motifs at these regions, nor did we ﬁnd IRF TFs
interacting with IRF2BP2 in our MS experiments. IRF2BP2 was
originally identiﬁed as an IRF2-interacting factor in a yeast two-
hybrid screen23. An IRF2–IRF2BP2 complex was recently
detected in the K562 human erythroleukaemia cell line52, and
IRF2 is expressed in MEL and primary murine erythroid
progenitor cells (45.0 RPKM as measured by RNA-Seq).
Whether this discrepancy reﬂects a species–speciﬁc difference
or differences in experimental systems is unclear. Nevertheless,
our combined analysis of IRF2BP2-binding sites and protein
partners does provide preliminary insight into the ETO2/LDB1-
independent functions of IRF2BP2. Genes bound only by
IRF2BP2 are signiﬁcantly enriched for functions related to
proliferation and apoptosis (Fig. 3b), and the cell-cycle
regulator cyclin-dependent kinase 11B interacts with IRF2BP2
(Fig. 7b). Interestingly, several studies have implicated IRF2BP2
in the regulation of cell survival25,26,53.
In agreement with our experiments in MEL cells, IRF2BP2 also
appears to be important for erythropoiesis and erythroid gene
regulation in vivo. Perinatal lethality of IRF2BP2-deﬁcient mice
precluded the analysis of adult erythropoiesis in our Irf2bp2
genetrap model. However, analysis of mid-gestation-deﬁnitive FL
erythropoiesis in these mice shows that IRF2BP2 is required for
an effective output of terminal erythroid differentiation (Fig. 7i,j;
Supplementary Fig. 7b). The exact nature of this defect remains to
be determined, but our experiments indicate the presence of a
partial differentiation block at the erythroblast stage, before
enucleation (Fig. 7i,j). Alternatively, the observed erythroblast
expansion could be a consequence of accelerated progenitor
differentiation or represent a compensatory mechanism, which
could also explain the partially exhausted progenitor
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compartment observed at E13.5 (Fig. 7i) and the premature
silencing of the immature Myb marker54 (Supplementary Figs 8
and 9). Gene expression analyses on puriﬁed erythroid progenitor
populations from wild-type and Irf2bp2trp/trp embryos reveal a
premature upregulation of late erythroid markers in IRF2BP2-
deﬁcient progenitors that is signiﬁcantly more pronounced at
E11.5 as compared with E13.5 (Supplementary Figs 8 and 9).
Intriguingly, we observe a strong upregulation of Irf2bpl in
Irf2bp2trp/trp progenitors and a delayed extinction of Irf2bpl
expression during in vivo erythroid maturation—in particular at
E13.5 (Supplementary Figs 8 and 9). As IRF2BP2 and IRF2BPL
reside in the same protein complexes (Fig. 7b), we hypothesize
that elevated IRF2BPL levels might compensate for a loss of
IRF2BP2 in vivo. Future investigations will reveal whether the
other IRF2BP family members indeed play a role in
erythropoiesis and in the regulation of primed erythroid gene
expression. While this paper was under review, IRF2BP2 was
shown to be important for macrophage-mediated
inﬂammation55, suggesting that IRF2BP2 may have a
multifaceted role in blood cell development and function.
In summary, we show that the control of developmentally
primed erythroid genes depends on the cooperative actions of
ETO2 and its novel binding partner IRF2BP2. Repression by the
ETO2–IRF2BP2 axis is lost during erythroid differentiation,
resulting in the full activation of the late erythroid-speciﬁc
transcriptome by the LDB1 complex. These results provide new
insight into the control of lineage-speciﬁc transcriptional pro-
grammes, as they suggest that an intricate balance between the
activating and repressive components of a TF complex underlies the
implementation of lineage-speciﬁc gene expression. Furthermore,
using an IRF2BP2-deﬁcient mouse model, we conﬁrm the relevance
of a functional Irf2bp2 allele for effective erythropoiesis in vivo.
Methods
Cell culture and Irf2bp2 genetrap animals. MEL (C88 clone56) and HEK 293T
(ATCC) cells were maintained in DMEM containing 10% FCS and penicillin/
streptomycin. ETO2-V5-Bio MEL cells expressing BirA were generated and
maintained as described previously5,21. Apicidin (Calbiochem, 178276) was
reconstituted in dimethylsulphoxide to obtain a 10mM stock. MEL cells were
treated by adding Apicidin directly to the medium to a ﬁnal concentration of
100 nM. Irf2bp2trp/wt C57BL/6 ES cells were produced by the Texas A&M Institute
for Genomic Medicine (College Station, TX) through the insertion of a genetrap
construct in the ﬁrst intron of the Irf2bp2 gene (clone IST11591C1). Genetrap
location was veriﬁed using standard PCR and sequencing methods. Mouse ES cells
were injected into blastocysts and implanted into pseudopregnant albino fosters
according to standard methods. Chimeric animals were further crossed to obtain
heterozygous founders and mice were further crossed on a mixed-FVB/N-C57BL/6
background. Mice were genotyped using a standard 3-primer PCR method. Up to
E18.5 of embryonic development, wild-type, heterozygous and homozygous
genetrap animals were obtained at the expected Mendelian ratio and with no visible
signs of developmental defects. Although Irf2bp2trp/wt animals were born in normal
numbers, Irf2bp2trp/trp mice were rarely born (o5% of the expected number).
Homozygous animals showed severe growth retardation and all died the ﬁrst weeks
after birth. Ethical approval was obtained from the Committee on the Ethics of
Animal Experiments (DEC) of the Erasmus MC as well as the French Ministry
of Agriculture regulations (DDPP92 animal facility registration number: B
92-032-02). All animal experiments were carried out according to institutional
and national guidelines.
(Co-)Immunoprecipitations and MS analysis in MEL cells. Protocols for the
preparation of nuclear extracts, streptavidin-mediated protein capture and LC–MS/
MS in MEL cells have been described previously21. On-bead proteolytic digestion
was performed by rapidly washing the beads containing bound ETO2-V5-Bio
complexes twice with trypsin digestion buffer (50mM NH4HCO3), after which to
each 50 ml of beads 100ml of trypsin digestion buffer and 10 ml of trypsin solution
(10 mgml 1) were added. Samples were incubated overnight at 37 C with shaking.
Digested samples were analysed by nanoﬂow LC–MS/MS on a LTQ-Orbitrap
(Thermo) mass spectrometer coupled to an 1100 series LC pump and autosampler
(Agilent), operating in positive mode and equipped with a nanospray source.
Peptide mixtures were trapped on a ReproSil C18 reversed-phase column
(Dr Maisch GmbH; column dimensions 1.5 cm 100mm, packed in-house) with a
ﬂow rate of 8 ml min 1. Peptide separation was performed using a ReproSil C18
reversed-phase column (Dr Maisch GmbH; column dimensions 15 cm 50mm,
packed in-house) using a linear gradient from 0 to 80% B (A¼ 0.1M formic acid;
B¼ 80% (v/v) acetonitrile, 0.1M formic acid) over 70min with a constant ﬂow rate
of 200 nlmin 1 using a splitter. The column eluent was directly sprayed into the
electrospray ionization source of the mass spectrometer. Mass spectra were
acquired in continuum mode; while fragmentation of the peptides was performed
in a data-dependent mode. Peak lists were automatically created from raw data ﬁles
using the Mascot Distiller software (version 2.1; MatrixScience). The Mascot search
algorithm (version 2.2, MatrixScience) was used for searching against the NCBInr
database (latest NCBInr release; taxonomy: Mus musculus). The peptide tolerance
was typically set to 10 p.p.m. and the fragment ion tolerance to 0.8 Da. A maximum
number of two missed cleavages by trypsin were allowed and carbamidomethylated
cysteine and oxidized methionine were set as ﬁxed and variable modiﬁcations,
respectively. The Mascot score cutoff value for a positive protein hit was set to 60.
Individual peptide MS/MS spectra with Mowse scores below 40 were checked
manually and either interpreted as valid identiﬁcations or discarded. Identiﬁed
proteins were ﬁltered against a database of background hits obtained from BirA-
expressing MEL cells. Proteins with no peptides identiﬁed in the BirA control
experiment or showing Mascot scores at least threefold higher than the control
were considered as positive hits, and were further validated by conventional co-IP
experiments (Fig. 1d; Supplementary Fig. 2b) For endogenous co-IPs, 0.5mg of
MEL nuclear extracts were diluted to reach 100mM KCl salt concentration using
Heng 0 buffer (20mM HEPES KOH pH 7.9, 20% glycerol, 0.25mM EDTA, 0.05%
NP-40). Extracts were treated with 1U Benzonase nuclease (Millipore). Protein
extracts were incubated with the speciﬁc antibody overnight at 4 C, followed by
addition of protein A or G Sepharose bead slurry (50 ml slurry per IP; Millipore)
and incubation at 4 C for 1 h. Beads were pelleted, washed three times in Heng 100
buffer (Heng buffer containing 100mM KCl) and boiled for 5min at 95 C in
Laemmli buffer before being subjected to western blot analysis. Proteomics analysis
of endogenous ETO2- and IRF2BP2-interacting proteins was carried out by direct
immune capture as described previously57. Brieﬂy, puriﬁcation of endogenous
protein complexes was performed by crosslinking 10 mg antibody (see below), or
control immunoglobulin to 50 ml protein G Sepharose beads (Amersham).
Antibody–bead complexes were blocked with 0.1mgml 1 insulin (Sigma),
0.2mgml 1 chicken egg albumin (Sigma) and 1% ﬁsh skin gelatin (Sigma) for 1 h
at room temperature and directly added to 1.5ml of MEL nuclear extracts
containing benzonase. After 3 h incubation at 4 C, antibody–bead complexes were
washed ﬁve times in C-100 buffer (20mM Hepes pH 7.6, 20% glycerol, 100mM
KCl, 1.5mM MgCl2, 0.2mM EDTA, 0.02% NP-40) and boiled in Laemmli buffer.
Proteins were loaded on a 4–12% acrylamide gel and lanes were cut for LC–MS/MS
analysis as described above. For MS analysis of ETO2- and IRF2BP2-interacting
proteins, two independent biological replicates (for both experimental and control
samples) were analysed to ensure reproducible and speciﬁc binding partner
identiﬁcation. The following antibodies were used: ETO2 G-20 (Santa Cruz,
sc9741), an IRF2BP2 rat monoclonal KT139 (clone 10G3, produced by Absea
Antibodies, Beijing), GFI1B B-7 (Santa Cruz, sc8559), LDB1 N-18 (Santa Cruz, sc-
11198), LSD1 (Abcam, ab17721), RUNX1 H-65 (Santa Cruz, sc28679), E2A V-18
(sc-349), HEB A-20 (sc-357), SSBP3 (Abcam, ab83815), V5 (Invitrogen, R960-25),
Flag M2 (Sigma, F1804) and haemagglutinin (HA) (Sigma, H6908).
Co-IPs and luciferase assays in HEK 293T cells. HEK 293T cells were trans-
fected with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
instructions. For ETO2–IRF2BP2 interaction domain mapping, we constructed a
series of Flag-tagged ETO2-deletion mutants, V5-IRF2BP2 and the HA-
IRF2BP2deltaRING-deletion mutant (see Fig. 2) in the pcDNA3.1 expression
vector (Invitrogen). HEK 293T cells were lysed 48 h post transfection in whole-cell
lysis buffer (20mM HEPES KOH pH 7.5, 150mM KCl, 10% glycerol, 2.5mM
EDTA, 5mM dithiothreitol, 0.1% Triton X-100 (Sigma) and protease inhibitor
cocktail (Roche)). Extracts were treated with 1U Benzonase nuclease (Millipore).
Protein extracts were incubated with the anti-Flag, anti-V5 or anti-HA antibodies
overnight at 4 C, followed by addition of protein A or G Sepharose bead slurry
(50 ml slurry per IP; Millipore) and incubation at 4 C for 1 h. Beads were pelleted,
washed three times in lysis buffer and boiled for 5min at 95 C in Laemmli buffer
before being subjected to western blot analysis. Full-length Kdm1a (LSD1) cDNA
was cloned in pcDNA3.1 for reporter assay experiments. The Gal4–ETO2 fusion
protein was generated by fusing full-length Cbfa2t3 cDNA sequence to a Gal4
DNA-binding domain in pcDNA3.1. The Gal4-responsive ﬁreﬂy luciferase
plasmid was a kind gift from Dr Jan van der Knaap (Erasmus MC). A Renilla
luciferase expressing vector (pRL-TK, Promega) was co-transfected and used for
normalization. Luciferase assays were performed using the Dual-Luciferase
Reporter Assay System (Promega) according to the manufacturer’s instructions54.
For rescue experiments, MEL cells transduced with shRNAs against cbfa2t3
(ETO2) or Irf2bp2 were transfected with expression vectors containing shRNA-
immune cDNAs encoding ETO2, IRF2BP2 or mutant versions of these proteins
using GeneCellin (BioCellChallenge). RNA extractions and gene expression
analysis by qPCR were carried out 48 h after transfection.
ChIP and ChIP-Seq experiments. Protocols for the preparation of chromatin
from MEL cells, IP and sample preparation for Illumina sequencing have been
previously described in great detail5,21. For NCOR1 ChIP-Seq, 108 MEL cells were
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crosslinked with 2mM disuccinimidyl glutarate (Thermo Fisher Scientiﬁc) and 1%
formaldehyde as previously described58. Antibodies used for ChIP (10 mg per
experiment) are identical to those used for IP (detailed above), except for GFI1B
(D-19 Santa Cruz, sc8559). Reads were mapped against NCBI build 37.1 of the
mouse genome (mm9) using Bowtie (version 2.0.0)59. Uniquely mapped reads were
extended to 200 bp in the 30 direction and were transformed into a genome-wide
read density (coverage) using custom R scripts. MACS (version 1.4.2)60, CCAT
(version 3.0)61 and in-house peak-calling software (available from the GitHub
repository, https://github.com/supatt/rChIPSeqTools.git) with default parameters
were used to comprehensively identify binding sites. We combined binding sites
identiﬁed by all three methods to deﬁne consensus-binding regions using
GenomicRanges. Binding regions predicted by each program were proﬁled on each
genomic location. We assigned value ‘1’ to the genomic locations that overlapped
with the predicted binding sites, and we assigned ‘0’ to the non-overlapping
locations. We then generated the whole-genome coverage vectors from all binding
regions of all methods and summed up these coverage vectors. We selected only
genomic regions that had a summed up coverage valueZ2 and a minimum region
length Z150 bp as candidate consensus-binding regions. Consensus-binding
regions were given P values based on a negative binomial distribution as modiﬁed
from PeakSeq62 and assigned P values were adjusted using the Benjamini–
Hochberg method. Candidate binding sites were then selected for the downstream
analysis based on the following criteria: read countsZ10 reads, fold changes (FCs)
Z2 compared with immunoglobulin (Ig)G control and adjusted P values r0.01.
To classify co-binding patterns, ETO2- and IRF2BP2-binding sites were combined
using GenomicRanges (using the ‘ﬁndOverlaps’ function with the minimum
overlap regions¼ 250 bp from the peak centre). Binding signal coverage for each
site was then normalized to obtain equal levels of background signal in both
antibody and IgG control experiments (normalization method was modiﬁed from
Peakseq62). Normalized coverage for the IgG control experiment was subtracted
from the normalized coverage for the Antibody experiment. We next retrieved the
subtracted coverage within±0.5 kb relative to the centre of each binding site and
calculated the standard z-scores in each sub-window (25 bp). The matrix of
standard z-scores per individual binding site was then subjected to K-means
(K¼ 3) clustering. Clustering analysis results were visualized with Java Treeview63.
After K-means clustering, we selected representative binding sites for each co-
binding pattern (1,760 for ETO2-only, 2,730 for ETO2/IRF2BP2 and 5 random sets
of 4,000 IRF2BP2-only). We retrieved repeat-masked 200-bp DNA sequences
centred on each binding site and removed the binding sites that contain Z150 bp
repeat-masked DNA. We next performed de novo motif discovery using MEME64
with a minimum motif width of 5 bp and a maximum number of 10 motifs as the
required parameters. We excluded motifs supported by r100 sites and removed
repeat motifs. ‘IRF2BP2-only’ category motifs were selected based on their
consistent identiﬁcation in the ﬁve random sets. Results from MEME were
subjected to an in-house ChIP-Seq analysis pipeline (available from the GitHub
repository, https://github.com/supatt/rChIPSeqTools.git) to generate motif logos
and to calculate the proportion of motif containing sites. Derived motifs were then
compared with known motifs in the JASPAR database65 using Tomtom66 with
parameters: ‘-min-overlap 4 -dist pearson -evalue -thresh 0.05’. Online GREAT31
was used to assign TF-binding sites to genes and identify associated biological
processes. Different GREAT analysis parameters were tested and yielded highly
comparable results. Results using the ‘single nearest gene method (within 1Mb)’
parameter are shown.
Real-time qPCR. For gene expression analysis, RNA extractions were performed
using TRIPure (Sigma) and cDNA synthesized using SuperScript II reverse tran-
scriptase and Oligo(dT) primers (Invitrogen). ChIP DNA or cDNA were used as
template in triplicate qPCR reactions (Platinum Taq DNA polymerase, Invitrogen)
and analysed on a CFX96 system (Bio-Rad). SYBR Green (Invitrogen) was used for
quantiﬁcation. Gene expression values were normalized to Rnh1 mRNA levels54.
Primer sequences can be found in Supplementary Table 1.
RNAi and CRISPR/Cas9-engineered deletions. Lentivirus particles were pro-
duced as described54. shRNA sequences were obtained from the MISSION TRC
shRNA library (Sigma, for Kdm1a and Ncor1), designed manually and cloned into
pLKO.1 (for Irf2bp2; sh1: 50-CTCCAGACAAAGCATTAAA-30 and sh3:
50-CAACGGGTCTAAAGCAGTT-30) or described before (Cbfa2t3 (ref. 5)). For
Gﬁ1b KDs, MEL cells were transfected with FlexiTube Gﬁ1b siRNA #1 and #7
(SI01011227 and SI05169871, Qiagen) using HiPerfect transfection reagent
(Qiagen) according to the manufacturer’s instructions. Non-targeting shRNAs/
siRNAs were used as controls. Cells were harvested 48 or 72 h after transduction/
transfection and processed for RNA/protein extraction as described above. The
generation of knockout cell lines by CRISPR/Cas9 technology was carried out
as previously described67 using the pSpCas9(BB)-2A-Puro (PX459) vector
(obtained from Addgene). Small guide RNA sequences for targeted inactivation of
Cbfa2t3 and Irf2bp2 in MEL cells were designed using the CRISPOR webtool
(http://crispor.tefor.net/crispor.cgi). Combinations of two different guide RNAs
were used for each gene to delete critical exons (Cbfa2t3: 50-GACTGGGGCCTCA
CAAACGA-30 and 50-GAACGGTTGCAGGGACAGAG-30; Irf2bp2: 50-GGTCAA
CGGTTCTGCCGCGC-30 and 50-GGCTTTCCTGCTGACCAGCC-30). MEL cells
were transfected using Genecellin (BioCellChallenge), single clones were isolated
and targeted genomic deletions were veriﬁed by PCR and sequencing.
RNA sequencing. Total RNA was extracted from MEL or E13.5 sorted FL
populations using the RNeasy mini kit (Qiagen). After qPCR validation, RNA was
used for mRNA-sequencing on an Illumina HiSeq 2000 (standard TruSeq RNA-
sequencing protocol). At least two independent biological replicate samples were
sequenced and used for downstream analysis. Raw reads were mapped with
Tophat2 (version 2.0.10)68 against mouse genome NCBI build 37.1 (mm9) with
default parameters using ‘no-coverage-search’, and ‘segment-length 18’ as input
options. We next quantiﬁed the expression per UCSC RefSeq (mm9) gene to obtain
read count and RPKM values using the rpkmforgenes script. The non-adjusted read
counts for each gene were used for statistical calculation of global differential
expression using DESeq2 (ref. 69). Differentially expressed genes were selected at
an adjusted P value of r0.05 (Benjamini–Hochberg corrected). We selected
differentially expressed genes with log2 FCsZ0.5 and log2 FCr 0.5 in each KD
data set to generate the correlation plots shown in Fig. 5. We selected the top 142
differentially expressed genes (log2 FC Z1 and log2 FC r 1) from the Cbfa2t3
KD data set for the clustering analysis. We then retrieved all log2 FC values for the
142 genes in the other KD data sets. Hierarchical clustering and visualization were
performed using MeV (ref. 70). For Ingenuity Pathway Analysis (Qiagen), only
genes with a log2 FC Z0.5 or r 0.5 and a Pr0.05 were considered. Core
Analysis (standard settings) was used to extract Gene Ontology terms that were
associated with a gene set in a statistically signiﬁcant fashion.
Flow cytometry. E11.5–13.5 embryos were harvested and dissected to collect the
FL. Hundred microlitre of PBS containing 1 million single cells obtained from
whole E13.5 FLs were stained with 5 ng ml 1 CD71-FITC (553266) and Ter119-PE
(553673) antibodies (BD Pharmingen). Hoechst was used as a viability dye (Sigma),
and cells positive for Hoechst staining were excluded from further analysis (470%
of the total cell population consisted of viable cells). Flowcytometric analysis was
performed using a BD LSRFortessa ﬂowcytometer (BD Biosciences), collecting a
minimum of 10,000 events per sample. FACS sorting was performed with a BD
FACSAria III (BD Biosciences) using the above described staining protocol. At
least 1 million cells were sorted for RNA extraction.
Immunoﬂuorescence. MEL cells were ﬁxed on poly-prep glass slides (Sigma)
and ﬁxed in 4% paraformaldehyde for 15min at room temperature. Cells were
permeabilized with 0.1% Triton X-100, blocked with 0.5% bovine serum albumin/
0.15% glycin (in PBS) and incubated overnight with ETO2 or V5 antibodies at 4 C.
After a 2-h incubation with appropriate secondary antibodies at room temperature,
coverslips were mounted on glass slides with Vectashield (þDAPI, Vector
Laboratories).
Published genome-wide data sets used. The following publicly available data
sets were used: LDB1, GATA1 and ETO2 ChIP-Seq data (MEL, SRA ERA000161
(ref. 5)); RNA-Seq data (MEL/G1E/G1E-ER, ENCODE Penn State University;
available at the UCSC Genome Browser (mouse genome, mm9)); p300 ChIP-Seq
data (MEL, ENCODE Stanford/Yale; available at the UCSC Genome Browser
(mouse genome, mm9)); H3K27Ac ChIP-Seq data (MEL/FL E14.5/Brain,
ENCODE Ludwig Institute for Cancer Research; available at the UCSC Genome
Browser (mouse genome, mm9)); DNAse I-Seq data (MEL/FL E14.5/Brain,
ENCODE University of Washington; available at the UCSC Genome Browser
(mouse genome, mm9)); GATA1, TAL1 and RNAPII ChIP-Seq data (MEL/G1E/
G1E-ER, ENCODE Penn State University; available at the UCSC Genome Browser
(mouse genome, mm9)); microarray gene expression data (Fetal and adult
erythroid populations, ErythronDB database online35).
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